Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18132141 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2POLBALDH1A1TP53HTT | |
| SCHEMBL485162 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2POLBALDH1A1GAATP53 | |
| SCHEMBL20444769 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2POLBALDH1A1GAATP53 | |
| SCHEMBL14959503 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2POLBALDH1A1GAATP53 | |
| SCHEMBL20445062 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2POLBALDH1A1GAATP53 | |
| SCHEMBL9675197 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2POLBALDH1A1GAATP53 | |
| SCHEMBL1581725 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2POLBALDH1A1GAATP53 | |
| SCHEMBL20445056 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2POLBALDH1A1GAATP53 | |
| SCHEMBL16793690 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2POLBALDH1A1GAATP53 | |
| SCHEMBL20444767 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2POLBALDH1A1GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127333-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3280418-A1 | AZACARBAZOLE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016164284-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| EP-2375904-A1 | BIARYL CARBOXAMIDES | Merck Sharp & Dohme Corp. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010077624-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-7232833-B2 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | NOVEXEL (FR) | 2007-06-19 | — | — | US | disclosed |
| US-20040224946-A1 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | US | disclosed |
| EP-0275092-B1 | PROCESS FOR PREPARING (+)-1,2-DIHYDRO-3H-PYRROLO(1,2-A)PYRROLE-1,7-DICARBOXYLATES | SYNTEX (U.S.A.) INC. (US) | 1992-06-03 | — | — | EP | disclosed |
| US-4874872-A | Process for preparing (+)-2,3-dihydro-1H-pyrrolo[1,2-A]pyrrole-1,7-dicarboxylates | SYNTEX (U.S.A.) INC. (US) | 1989-10-17 | — | — | US | disclosed |
| US-4849526-A | Process for preparing (±)-2,3-dihydro-1H-pyrrolo[1,2-A]pyrrole-1,7-dicarboxylates | SYNTEX (U.S.A.) INC. (US) | 1989-07-18 | — | — | US | disclosed |
| EP-0275092-A1 | Process for preparing (+)-1,2-dihydro-3H-pyrrolo(1,2-a)pyrrole-1,7-dicarboxylates | SYNTEX (U.S.A.) INC. (US) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224946-A1 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | HRH2, HRH1, HRH3 | SMN1; SMN2 890/4885POLB 1043/4885ALDH1A1 2272/4885 |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, NR3C2 | SMN1; SMN2 1891/4885POLB 4307/4885ALDH1A1 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.